Long Focus Capital Management’s Caribou Biosciences CRBU Stock Holding History

Long Focus Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-65,000	Closed	-$311K	–	115
2023 Q3	$311K	Hold	65,000	–	–	0.01%	102
2023 Q2	$276K	Hold	65,000	–	–	0.01%	101
2023 Q1	$345K	Hold	65,000	–	–	0.02%	98
2022 Q4	$408K	Hold	65,000	–	–	0.03%	92
2022 Q3	$686K	Sell	65,000 -15,000	-19%	-$140K	0.07%	83
2022 Q2	$434K	Buy	+80,000	New	+$612K	0.05%	89

Other funds holding CRBU

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Long Focus Capital Management's CRBU Position: Q4 2023 in Review

Long Focus Capital Management sold out of Caribou Biosciences (CRBU) in Q4 2023, closing a stake of 65,000 shares — an estimated $311K sold.

Long Focus Capital Management first reported a position in CRBU in Q2 2022 and held it in 6 quarters. The position peaked at $686K in Q3 2022. 144 funds tracked by Wall St. Rank hold CRBU as of Q4 2023.

Long Focus Capital Management reported no remaining Caribou Biosciences position as of Q4 2023 after selling out during the quarter.
Long Focus Capital Management sold 65,000 Caribou Biosciences shares in Q4 2023, an estimated $311K.
Long Focus Capital Management first reported a position in Caribou Biosciences in Q2 2022 and held it in 6 quarters.
Long Focus Capital Management's Caribou Biosciences position peaked at $686K in Q3 2022.
144 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2023.

Based on Long Focus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.